89Bio's NASH drug meets main goals of mid-stage study

March 22, 2023 04:42 AM PDT | By Reuters
Follow us on Google News:

(Adds updated share movement, and trial details)

March 22 (Reuters) - Drug developer 89Bio Inc said on Wednesday its treatment for a liver disease called non-alcoholic steatohepatitis met the main goals of a mid-stage trial, sending its shares up 50% in premarket trading.

The company's experimental drug, Pegozafermin, demonstrated at least one-stage fibrosis improvement without worsening of NASH and NASH resolution without worsening of fibrosis in both trial doses.

89Bio said the data supports advancement to late-stage development.

(Reporting by Pratik Jain in Bengaluru; Editing by Sriraj Kalluvila)


The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.